Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Stopped: REVIVE-FR Registry Withdrawn before enrolling
- Stopped: Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL Trial terminated
- Stopped: Tocilizumab, Ipilimumab, and Nivolumab · Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Trial terminated
- Stopped: Unilateral M1 Anodal tDCS to Enhance Learning in a Gross Movement Videogame Task Trial terminated
- Stopped: Low Intensity Focused Ultrasound for Binge Eating Disorder Trial terminated
- Stopped: Quality of Life After Hyperbaric Oxygen Therapy in Post-COVID Patients Trial status changed: Active, Not Recruiting → Withdrawn
- Stopped: Language Outcomes in Deaf Children Trial terminated
- Stopped: Use of Focused Ultrasound and DCE K-trans Imaging to Evaluate Permeability of the Blood-Brain Barrier Trial status changed: Enrolling by Invitation → Withdrawn
- Stopped: Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer Trial terminated
- Stopped: Operator Radiation Exposure During Image-Guided Robotic-Assisted Bronchoscopy: A Multicenter Prospective Cohort Study Trial status changed: Recruiting → Withdrawn
- Stopped: Non-invasive Cranial Electrical Stimulation for Mealtime Anxiety · Eating Disorders Trial terminated
- Notable: Collection of Venous and Capillary Blood Samples Research, Optimization and Calibration of New Diagnostic Devices Enrollment reduced: 30000 → 12000 participants
- Notable: PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer Enrollment reduced: 534 → 130 participants
- Notable: Opioid-Free Anesthesia in Colorectal Surgery, 2025 (OFA-CRC-2025) Enrollment reduced: 200 → 100 participants
- Notable: Intravenous Versus Oral Treatment of the Main Acute Infections Enrollment reduced: 4000 → 2640 participants
- Notable: Community Study to Increase Mammogram Screening Among Overdue Women Enrollment reduced: 15000 → 1500 participants
- Notable: Intensive Weight Loss Intervention Versus Bariatric Surgery · Severe and Complex Obesity: the LightBAR Randomised Trial Enrollment reduced: 500 → 316 participants
- Notable: Harnessing Artificial Intelligence for Diagnosing Androgenetic Alopecia: A Training and Validation Study Enrollment reduced: 400 → 240 participants
- Notable: 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream · Lichen Sclerosus Primary endpoint(s) modified
- Notable: Garetosmab Versus Placebo Administered Intravenously (IV) · Fibrodysplasia Ossificans Progressiva (FOP) Results posted: Nov 17, 2026
- Notable: Orally Administered JBI-802 · Essential Thrombocythemia (ET) and Polycythemia Vera (PV) With Thrombocytosis Primary and study completion dates pushed to Jan 30, 2031
- Notable: Trials of SHR-8203 Injection · Advanced Solid Tumors Recruitment opened
- Notable: HER3-DXd · Locally Advanced or Metastatic Solid Tumors Primary completion pushed from Sep 1, 2027 to Nov 19, 2030
- Notable: SHR-7590 in Chinese Healthy Participants and · Moderate-to-severe Inflammatory Bowel Disease Primary completion pushed from Jan 2027 to Mar 31, 2028
- Notable: Comparative Self-collection for Cervical Cancer Screening Pivotal Study Primary endpoint(s) modified
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates